Compare RJF & ZTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RJF | ZTS |
|---|---|---|
| Founded | 1962 | 1952 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.7B | 32.5B |
| IPO Year | 2005 | 2012 |
| Metric | RJF | ZTS |
|---|---|---|
| Price | $174.71 | $76.85 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 12 | 12 |
| Target Price | ★ $174.67 | $154.18 |
| AVG Volume (30 Days) | 906.9K | ★ 5.5M |
| Earning Date | 04-22-2026 | 05-07-2026 |
| Dividend Yield | 1.39% | ★ 1.86% |
| EPS Growth | 6.19 | ★ 10.05 |
| EPS | ★ 8.52 | 3.08 |
| Revenue | ★ $15,912,000,000.00 | $9,467,000,000.00 |
| Revenue This Year | $13.28 | $5.63 |
| Revenue Next Year | $7.76 | $4.77 |
| P/E Ratio | ★ $20.74 | $25.05 |
| Revenue Growth | ★ 6.63 | 2.28 |
| 52 Week Low | $138.82 | $71.00 |
| 52 Week High | $182.73 | $156.49 |
| Indicator | RJF | ZTS |
|---|---|---|
| Relative Strength Index (RSI) | 53.31 | 51.07 |
| Support Level | $175.02 | $73.02 |
| Resistance Level | $182.73 | $78.74 |
| Average True Range (ATR) | 3.28 | 2.92 |
| MACD | -1.10 | 0.33 |
| Stochastic Oscillator | 40.39 | 60.76 |
Raymond James Financial is a diversified financial services firm that provides wealth management, investment banking, asset management, and capital markets services to individuals, corporations, and municipalities. The firm maintains an extensive catalogue of products and services across its business lines. However, the wealth management franchise generates the bulk of its revenues and earnings through a vast network of more than 8,900 independent and employee-affiliated advisors, who collectively managed over $1.7 trillion in client assets as of fiscal year-end 2025. While Raymond James maintains a global footprint, the company derives over 90% of its revenue and an even larger percentage of its operating income, from the United States.
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on) and nearly 65% from companion animal (dogs, horses, cats) products. Its US business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.